Tesamorelin

Tesamorelin is the full-length human GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus that enhances receptor binding affinity and metabolic stability. It's the only GHRH analog that received FDA approval — cleared for HIV-associated lipodystrophy in 2010 — which means it carries a body of human safety and efficacy data that other GHRH analogs simply don't have. CAS: 218949-48-5. MW 5,135.9 Da.

Why the Full 44-Residue Sequence Matters

The mechanism follows standard GHRH biology: pituitary GHRH-R activation drives pulsatile GH secretion, downstream IGF-1 rises, and GH-mediated lipolysis preferentially targets visceral adipose depots. The full 44-amino-acid sequence is relevant here because the C-terminal residues of GHRH contribute to receptor binding — truncated analogs like sermorelin (1-29) have reduced potency relative to the complete sequence.

FDA approval means Phase 3 controlled trials. For tesamorelin, those trials generated endpoints beyond just GH and IGF-1: visceral adipose tissue measurements by MRI, liver fat quantification, cardiovascular risk biomarkers, and long-term safety data in immunocompromised subjects. That specific dataset — visceral fat, liver endpoints, measured over 26-52 weeks in human subjects — isn't available for sermorelin, CJC-1295, or other GHRH analogs. For NAFLD models, HIV-associated lipodystrophy research, or visceral adiposity studies requiring a clinical-grade reference compound, tesamorelin is the appropriate choice.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.